Nonalcoholic fatty liver disease and atherosclerosis

Internal and Emergency Medicine

Volumn 7, Issue SUPPL. 3, 2012, Pages 297-305

  Gaudio, Eugenio ^a   Nobili, Valerio ^b   Franchitto, Antonio ^a,c   Onori, Paolo ^d   Carpino, Guido ^e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c Eleonora Lorillard Spencer Cenci Foundation   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

Adipokine; Atherosclerosis; NAFLD; NASH; Vulnerable plaque

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; ATHEROSCLEROSIS; DISEASE COURSE; FATTY LIVER; HUMAN; IMMUNOLOGY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; RISK FACTOR;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FATTY LIVER; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 84867732521     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-012-0826-5     Document Type: Article

References (54)

1. Stary HC, Chandler AB, Glagov S et al (1994) A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb 14(5): 840-856.
2. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20(5): 1262-1275.
3. Gaudio E, Carpino G, Grassi M, Musca A (2006) Morphological aspects of atherosclerosis lesion: past and present. Clin Ter 157(2): 135-142.
4. Donnelly P, Maurovich-Horvat P, Vorpahl M et al (2010) Multimodality imaging atlas of coronary atherosclerosis. JACC Cardiovasc Imaging 3(8): 876-880.
5. Finn AV, Kolodgie FD, Virmani R (2010) Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol 30(2): 177-181.
6. Kolodgie FD, Burke AP, Nakazawa G, Virmani R (2007) Is pathologic intimal thickening the key to understanding early plaque progression in human atherosclerotic disease? Arterioscler Thromb Vasc Biol 27(5): 986-989.
7. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R (1997) Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336(18): 1276-1282.
8. Naghavi M, Libby P, Falk E et al (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108(15): 1772-1778.
9. Naghavi M, Libby P, Falk E et al (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108(14): 1664-1672.
10. Virmani R, Burke AP, Farb A, Kolodgie FD (2006) Pathology of the vulnerable plaque. J Am Coll Cardiol 47(8 Suppl): C13-C18.
11. Stone GW, Maehara A, Lansky AJ et al (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364(3): 226-235.
12. Chiu JJ, Chien S (2011) Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 91(1): 327-387.
13. Li YS, Haga JH, Chien S (2005) Molecular basis of the effects of shear stress on vascular endothelial cells. J Biomech 38(10): 1949-1971.
14. Chiu JJ, Usami S, Chien S (2009) Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. Ann Med 41(1): 19-28.
15. Dimmeler S, Haendeler J, Zeiher AM (2002) Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipidol 13(5): 531-536.
16. Hsiai TK, Cho SK, Wong PK, Ing M, Salazar A, Sevanian A, Navab M, Demer LL, Ho CM (2003) Monocyte recruitment to endothelial cells in response to oscillatory shear stress. FASEB J 17(12): 1648-1657.
17. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12(3): 204-212.
18. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16): 1685-1695.
19. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J (2002) Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417(6890): 750-754.
20. Zernecke A, Shagdarsuren E, Weber C (2008) Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28(11): 1897-1908.
21. Butcher MJ, Galkina EV (2012) Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol 3: 44.
22. Ley K, Miller YI, Hedrick CC (2011) Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol 31(7): 1506-1516.
23. Moore KJ, Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145(3): 341-355.
24. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5(12): 953-964.
25. Butcher M, Galkina E (2011) Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost 106(5): 787-795.
26. Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32(5): 593-604.
27. Hansson GK, Robertson AK, Soderberg-Naucler C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1: 297-329.
28. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346(16): 1221-1231.
29. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C (2011) Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 17(26): 3082-3091.
30. Bieghs V, Rensen PC, Hofker MH, Shiri-Sverdlov R (2012) NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis 220(2): 287-293.
31. Sookoian S, Gianotti TF, Rosselli MS, Burgueno AL, Castano GO, Pirola CJ (2011) Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 218(2): 378-385.
32. Targher G, Day CP, Bonora E (2011) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363(14): 1341-1350.
33. Adams LA, Angulo P (2005) Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22(9): 1129-1133.
34. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G (2005) Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42(2): 473-480.
35. Sookoian S, Pirola CJ (2008) Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 49(4): 600-607.
36. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G (2007) Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30(5): 1212-1218.
37. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E (2010) Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 53(4): 713-718.
38. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M (2009) Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 35(3): 277-287.
39. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP (2008) NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 16(6): 1394-1399.
40. Marra F, Bertolani C (2009) Adipokines in liver diseases. Hepatology 50(3): 957-969.
41. Ikejima K, Takei Y, Honda H et al (2002) Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122(5): 1399-1410.
42. Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10): 772-783.
43. Nobili V, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, Onori P, Alvaro D, Gaudio E (2012) Hepatic progenitor cells activation, fibrosis and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology. doi: 10. 1002/hep. 25742.
44. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA (2002) Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35(4): 762-771.
45. Bertolani C, Sancho-Bru P, Failli P et al (2006) Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 169(6): 2042-2053.
46. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H (2005) Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54(1): 117-121.
47. Beier JI, Guo L, von Montfort C, Kaiser JP, Joshi-Barve S, Arteel GE (2008) New role of resistin in lipopolysaccharide-induced liver damage in mice. J Pharmacol Exp Ther 325(3): 801-808.
48. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121(6): 2111-2117.
49. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, Peterson CA, Kern PA (2010) Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 299(6): E1016-E1027.
50. Marzioni M, Alpini G, Saccomanno S et al (2007) Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology 133(1): 244-255.
51. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4): 1409-1439.
52. Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ (2010) Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 151(10): 4678-4687.
53. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, Yoon JW, Jun HS (2007) Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 56(6): 1671-1679.
54. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14(2): 72-81.